You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023238010
Dec 20234807
Jan 20247106
Feb 20244601
Mar 20241604
Apr 20242807
May 20241200
Jun 20244205
Jul 20241608
Aug 20241803
Sep 20241801
Oct 20242004
Nov 20242201
Dec 20242606
Jan 20252807
Feb 2025206
Mar 2025002
Apr 2025106
May 2025003
Jun 2025004
Total652091